1. Home
  2. LADR vs TRVI Comparison

LADR vs TRVI Comparison

Compare LADR & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ladder Capital Corp

LADR

Ladder Capital Corp

HOLD

Current Price

$10.35

Market Cap

1.3B

Sector

Real Estate

ML Signal

HOLD

Logo Trevi Therapeutics Inc.

TRVI

Trevi Therapeutics Inc.

HOLD

Current Price

$13.86

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LADR
TRVI
Founded
2008
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.4B
IPO Year
2013
2019

Fundamental Metrics

Financial Performance
Metric
LADR
TRVI
Price
$10.35
$13.86
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
11
Target Price
$12.25
$21.55
AVG Volume (30 Days)
992.2K
1.7M
Earning Date
04-23-2026
05-05-2026
Dividend Yield
8.98%
N/A
EPS Growth
N/A
31.91
EPS
0.02
N/A
Revenue
N/A
N/A
Revenue This Year
$31.66
N/A
Revenue Next Year
$16.92
N/A
P/E Ratio
$515.00
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.61
$5.38
52 Week High
$11.92
$16.12

Technical Indicators

Market Signals
Indicator
LADR
TRVI
Relative Strength Index (RSI) 54.72 55.12
Support Level $10.16 $10.07
Resistance Level $10.54 $13.97
Average True Range (ATR) 0.17 0.87
MACD 0.01 -0.16
Stochastic Oscillator 59.72 24.92

Price Performance

Historical Comparison
LADR
TRVI

About LADR Ladder Capital Corp

Ladder Capital Corp is an internally-managed real estate investment trust that is in commercial real estate finance. The company originates and invests in a diverse portfolio of commercial real estate and real estate-related assets, focusing on senior secured assets. The company's investment activities include: (i) Primary business of originating senior first mortgage fixed and floating rate loans collateralized by commercial real estate with flexible loan structures; (ii) owning and operating commercial real estate, including net leased commercial properties; and (iii) investing in investment-grade securities secured by first mortgage loans on commercial real estate. The company has three reportable segments: Loans, which derive maximum revenue; Securities; and Real Estate.

About TRVI Trevi Therapeutics Inc.

Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.

Share on Social Networks: